For research use only. Not for therapeutic Use.
Aselizumab（Cat No.:I042172）is an investigational monoclonal antibody that targets the immune checkpoint receptor PD-1 (programmed cell death protein 1), which is expressed on T-cells. PD-1 suppresses immune responses, allowing tumors to evade detection. By blocking PD-1, aselizumab aims to restore T-cell activation and enhance the immune system’s ability to recognize and eliminate cancer cells. It is being studied in clinical trials for its potential to treat various cancers, including solid tumors and hematologic malignancies. The goal is to improve patient outcomes by enhancing the body’s natural immune response to cancer.
| Catalog Number | I042172 |
| CAS Number | 395639-53-9 |
| Purity | ≥95% |
